Optogenetic Chimeric Polypeptide for Inducible Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modeling neurodegenerative diseases fail to accurately mimic human neuropathology as they rely on genetic mutations or overexpression of proteins, which are not representative of the vast majority of patients, leading to a lack of translatability in treatment approaches.
Innovation Solution
Development of chimeric polypeptides containing light-induced oligomerization domains and low complexity domains from neurodegenerative disease target proteins, which can be induced to oligomerize and aggregate using blue light, mimicking the pathological hallmarks of neurodegenerative diseases without the need for genetic mutations or overexpression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic mutations or gross overexpression of proteins are used to model neurodegenerative diseases, then disease pathology can be induced in cell lines and animal models, but the models do not accurately mimic patient pathology and lack translatability
Solution Approach 1:
The patent changes the induction mechanism from genetic mutations or constitutive overexpression to light-induced oligomerization. By using optogenetic tools (CRY2/CIB1 or PhyB/PIF systems), the protein aggregation state can be dynamically controlled through light exposure, allowing researchers to induce pathology only when needed and revert to normal states by removing light stimulation. This parameter change enables more physiologically relevant modeling that better translates to human disease progression.
Solution Approach 2:
The patent introduces temporal and spatial dynamics to disease modeling. Instead of static genetic mutations or continuous overexpression, the system allows dynamic induction and reversal of protein aggregation through light control. Researchers can induce oligomerization at specific time points, control the duration of aggregation, and even reverse the process by removing light stimulation, creating a more flexible and translationally relevant disease model.
2Reliability
If constitutive expression of disease proteins is used, then pathology is continuously present, but spatial and temporal control of disease induction is lost
Solution Approach 1:
The patent replaces the mechanical/genetic control system (constitutive expression from promoters) with an optical control system. Light activation of optogenetic domains (CRY2, CIB1, PhyB, PIF) provides precise spatial and temporal control over protein oligomerization. This substitution allows researchers to induce pathology in specific cell types or brain regions by targeting light delivery, and to control the timing of induction independently of protein expression levels.
Solution Approach 2:
The patent introduces light-sensitive intermediary domains (CRY2, CIB1, PhyB, PIF) that mediate between light stimulation and protein aggregation. These intermediary optogenetic modules act as controllable switches that translate optical signals into biochemical events (oligomerization), providing a layer of control that decouples protein expression from aggregation induction and enables precise spatiotemporal manipulation of disease pathology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the spatial and temporal induction of neurodegenerative disease pathologies in cell models, better recapitulating human disease conditions and enabling the development of more applicable and inducible disease models for drug screening and treatment research.
Implementation Method 1
a first nucleotide sequence encoding a light-induced oligomerization domain selected from the group consisting of VVD LOV, NcVVD, CRY2OLIG, CRYPHR, NcVVDY50W, NcLOV, VfAU1, YtvA, EL222, RsLOV
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present disclosure relates to compounds, compositions, and methods for the inducing neurodegenerative disease pathologies. In one aspect, disclosed herein is a nucleotide sequence encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease target protein. Disclosed herein is a method of inducing a neurodegenerative disease pathology in a cell, comprising the steps: introducing into the cell an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter; expressing the chimeric polypeptide; and inducing oligomerization of the chimeric polypeptide by stimulation with blue light.